Skip to main content

Fading With Time of PD-L1 Immunoreactivity in Non-Small Cells Lung Cancer Tissues: A Methodological Study.

Giunchi F, Degiovanni A, Daddi N, Fiorentino M, Dell'Amore A, Agostinelli C, Ardizzoni A, Trisolini R

Publication: Appl Immunohistochem Mol Morphol (2018) • Vol 26 • Page 489-494PMID: 27801735View on PubMed

Purpose

This study compared programmed death-ligand 1 (PD-L1) immunohistochemical staining between squamous cell and adenocarcinoma non-small cell lung cancer (NSCLC) specimens and between specimens collected in 2014 and 2015 that were stored as FFPE blocks.

Conclusion

Of the 58 cases in the study, 48 were classified as PD-L1 positive, with immunopositive staining restricted to tumor-infiltrating lymphocytes in 24 cases, restricted to tumor cells in one case, and detected in both tumor cells and tumor-infiltrating lymphocytes in 23 cases. PD-L1 immunoreactivity in tumor cells was found in a significantly higher percentage of squamous cell carcinoma specimens than adenocarcinoma specimens (26% versus 15%, P=0.016), and squamous cell carcinoma specimens were also more likely to have a score of 2+ or 3+ than adenocarcinoma specimens (5% versus 2% and 7% versus 0%, P=0.033). The percentage of tumor-infiltrating lymphocytes with positive PD-L1 immunoreactivity scores were similar for adenocarcinoma and squamous cell carcinoma specimens (score of 1+: 29% versus 15%, respectively; score of 2+: 9% versus 12%, respectively; and score of 3+: 7% versus 8%, respectively). In both tumor cells and tumor-infiltrating lymphocytes, the extent of PD-L1 immunoreactivity increased with tumor grade (P=0.013). PD-L1 scores in tumor cells were lower in the specimens processed in 2014 than those processed in 2015 (score of 1+: 15% versus 12%; score of 2+: 0% versus 7%; score of 3+: 0% versus 7%) but the PD-L1 score distribution in tumor-infiltrating lymphocytes was comparable between 2014 and 2015 specimens (score of 1+; 24% versus 20%; score of 2+: 6% versus 14%; score of 3+: 7% versus 8%). The authors reported similar results using another PD-L1 antibody. The authors also state that CD8 immunostaining was unaffected by block age.

Studies (1)

Purpose

This study compared programmed death-ligand 1 (PD-L1) IHC staining between squamous cell and adenocarcinoma non-small cell lung cancer (NSCLC) and between specimens collected in 2014 and 2015 that were stored as FFPE blocks. The study included 58 NSCLC resection pathology specimens (34 adenocarcinoma and 24 squamous cell carcinoma). The cases evaluated included 6 well-differentiated grade G1, 17 moderately differentiated G2, and 35 poorly differentiated G3. All specimens were fixed in  4% neutral buffered formalin for 8-48 h at room temperature, then were embedded in paraffin. Blocks were stored in the dark at room temperature (18-25°C). Tissue microarrays were constructed from four 0.6 mm tumor-containing cores and one core from the same block that contained normal lung tissue. Sections of the tissue microarray were immunohistochemically stained using an antibody against PD-L1. Immunopositive staining was assessed by two pathologists and cases were classified as 1+ when <5% of cells were positive, 2+ when >5 % and <50% of cells were positive, or 3+ when > 50% of cells were positive.

Summary of Findings

Of the 58 cases in the study, 48 were classified as PD-L1 positive, with immunopositive staining restricted to tumor-infiltrating lymphocytes in 24 cases, restricted to tumor cells in one case, and detected in both tumor cells and tumor-infiltrating lymphocytes in 23 cases. PD-L1 immunoreactivity in tumor cells was found in a significantly higher percentage of squamous cell carcinoma specimens than adenocarcinoma specimens (26% versus 15%, P=0.016), and squamous cell carcinoma specimens were also more likely to have a score of 2+ or 3+ than adenocarcinoma specimens (5% versus 2% and 7% versus 0%, P=0.033). The percentage of tumor-infiltrating lymphocytes with positive PD-L1 immunoreactivity scores were similar for adenocarcinoma and squamous cell carcinoma specimens (score of 1+: 29% versus 15%, respectively; score of 2+: 9% versus 12%, respectively; and score of 3+: 7% versus 8%, respectively). In both tumor cells and tumor-infiltrating lymphocytes, the extent of PD-L1 immunoreactivity increased with tumor grade (P=0.013). PD-L1 scores in tumor cells were lower in the specimens processed in 2014 than those processed in 2015 (score of 1+: 15% versus 12%; score of 2+: 0% versus 7%; score of 3+: 0% versus 7%) but the PD-L1 score distribution in tumor-infiltrating lymphocytes was comparable between 2014 and 2015 specimens (score of 1+; 24% versus 20%; score of 2+: 6% versus 14%; score of 3+: 7% versus 8%). The authors reported similar results using another PD-L1 antibody. The authors also state that CD8 immunostaining was unaffected by block age.

  • Biospecimens

    TissueLung
  • Preservation Types

    Formalin
  • Diagnoses

    NeoplasticCarcinoma
    NeoplasticNormal Adjacent
  • Platforms

    ProteinImmunohistochemistry
  • Pre-analytical Factors

    ClassificationPre-Analytical FactorValue(s)
    PreaquisitionDiagnosis/ patient condition
    Adenocarcinoma
    Squamous cell carcinoma specimens
    PreaquisitionPrognostic factor
    Grade 1
    Grade 2
    Grade 3
    StorageStorage duration
    Collected in 2014
    Collected in 2015